Hepatitis B is a viral infection caused due to transmission of the virus through contact with the blood or other body fluids of an infected person. It is considered as a serious occupational hazard for healthcare professionals, which affects the liver, causing acute and chronic diseases. Hence, Chinese hamster ovary cell (CHO) hepatitis B vaccine is considered to be the safe and effective method to prevent the hepatitis B infection. The major factor that fuels the growth of the market are increase in prevalence of hepatitis B infection worldwide. For example, approximately 887,000 deaths due to hepatitis B infection were recorded in 2015 across the globe. However, inherent disadvantages of using recombinant Chinese hamster ovary cell (CHO) to design hepatitis B vaccines restrains the growth of the market. Conversely, increase in government focus to promote (CHO) hepatitis B vaccination for adults and extensive research carried out for the same are expected to offer lucrative opportunities for the market.
Highlights
The global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine include Merck & Co., Inc., GlaxoSmithKline Plc, Pfizer Inc., Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Serum Institute of India and Johnson & Johnson, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine.
The Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Merck & Co., Inc.
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson
Segment by Type
Pediatric Hepatitis B (CHO) Vaccine
Adult Hepatitis B (CHO) Vaccine
Segment by Application
Hospitals
Clinics
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Overview
1.1 Product Overview and Scope of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine
1.2 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Segment by Type
1.2.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Pediatric Hepatitis B (CHO) Vaccine
1.2.3 Adult Hepatitis B (CHO) Vaccine
1.3 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Segment by Application
1.3.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Size Estimates and Forecasts
1.4.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue 2018-2029
1.4.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales 2018-2029
1.4.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Competition by Manufacturers
2.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine, Product Type & Application
2.7 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Competitive Situation and Trends
2.7.1 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Players Market Share by Revenue
2.7.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Retrospective Market Scenario by Region
3.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Region: 2018-2029
3.2.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Region: 2018-2023
3.2.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Region: 2024-2029
3.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Region: 2018-2029
3.3.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Region: 2018-2023
3.3.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Region: 2024-2029
3.4 North America Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Facts & Figures by Country
3.4.1 North America Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Country (2018-2029)
3.4.3 North America Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Facts & Figures by Country
3.5.1 Europe Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Country (2018-2029)
3.5.3 Europe Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Facts & Figures by Country
3.7.1 Latin America Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Type (2018-2029)
4.1.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Type (2018-2023)
4.1.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Type (2024-2029)
4.1.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Type (2018-2029)
4.2.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Type (2018-2023)
4.2.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Type (2024-2029)
4.2.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Application (2018-2029)
5.1.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Application (2018-2023)
5.1.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales by Application (2024-2029)
5.1.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Application (2018-2029)
5.2.1 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Application (2018-2023)
5.2.2 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue by Application (2024-2029)
5.2.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck & Co., Inc.
6.1.1 Merck & Co., Inc. Corporation Information
6.1.2 Merck & Co., Inc. Description and Business Overview
6.1.3 Merck & Co., Inc. Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck & Co., Inc. Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Product Portfolio
6.1.5 Merck & Co., Inc. Recent Developments/Updates
6.2 GlaxoSmithKline Plc
6.2.1 GlaxoSmithKline Plc Corporation Information
6.2.2 GlaxoSmithKline Plc Description and Business Overview
6.2.3 GlaxoSmithKline Plc Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GlaxoSmithKline Plc Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Product Portfolio
6.2.5 GlaxoSmithKline Plc Recent Developments/Updates
6.3 Pfizer Inc.
6.3.1 Pfizer Inc. Corporation Information
6.3.2 Pfizer Inc. Description and Business Overview
6.3.3 Pfizer Inc. Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Inc. Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Product Portfolio
6.3.5 Pfizer Inc. Recent Developments/Updates
6.4 Sanofi Pasteur
6.4.1 Sanofi Pasteur Corporation Information
6.4.2 Sanofi Pasteur Description and Business Overview
6.4.3 Sanofi Pasteur Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sanofi Pasteur Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Product Portfolio
6.4.5 Sanofi Pasteur Recent Developments/Updates
6.5 CSL Limited
6.5.1 CSL Limited Corporation Information
6.5.2 CSL Limited Description and Business Overview
6.5.3 CSL Limited Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 CSL Limited Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Product Portfolio
6.5.5 CSL Limited Recent Developments/Updates
6.6 Emergent Biosolutions
6.6.1 Emergent Biosolutions Corporation Information
6.6.2 Emergent Biosolutions Description and Business Overview
6.6.3 Emergent Biosolutions Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Emergent Biosolutions Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Product Portfolio
6.6.5 Emergent Biosolutions Recent Developments/Updates
6.7 Serum Institute of India
6.6.1 Serum Institute of India Corporation Information
6.6.2 Serum Institute of India Description and Business Overview
6.6.3 Serum Institute of India Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Serum Institute of India Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Product Portfolio
6.7.5 Serum Institute of India Recent Developments/Updates
6.8 Johnson & Johnson
6.8.1 Johnson & Johnson Corporation Information
6.8.2 Johnson & Johnson Description and Business Overview
6.8.3 Johnson & Johnson Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Johnson & Johnson Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Product Portfolio
6.8.5 Johnson & Johnson Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Industry Chain Analysis
7.2 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Production Mode & Process
7.4 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales and Marketing
7.4.1 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Sales Channels
7.4.2 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Distributors
7.5 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Customers
8 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Dynamics
8.1 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Industry Trends
8.2 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Drivers
8.3 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Challenges
8.4 Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Merck & Co., Inc.
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson
*If Applicable.